In ESCC, TSGA10 down-regulation is shown to be associated with a progressive clinical stage, and in vivo assays suggest TSGA10 knockdown significantly accelerates tumor growth and leads to larger tumor volumes [30]. The gene discussed is TSGA10; the disease is neoplasm.